Lung Cancer Clinical Trial
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Summary
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.
Eligibility Criteria
Inclusion Criteria:
Eastern Cooperative Oncology Group performance status of 0 or 1
Histological or cytological diagnosis of Stage IIB, IIIA, and select IIIB NSCLC of either non-squamous or squamous histology
Participants must have had complete resection of NSCLC
Participants must have received between one to four cycles of adjuvant histology-based platinum doublet chemotherapy
Participants must have recovered adequately from surgery and from adjuvant chemotherapy
Tumor cell PD-L1 expression at >/= 1%
Adequate hematologic and end-organ function.
Exclusion Criteria:
Any history of prior NSCLC within the last 5 years
Any evidence of residual disease or disease recurrence following surgical resection of NSCLC, or during or following adjuvant chemotherapy
NSCLC known to have mutation in the EGFR gene or an ALK fusion oncogene
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 27 Locations for this study
Cerritos California, 90703, United States
Marietta Georgia, 30060, United States
Springfield Illinois, 62702, United States
Albuquerque New Mexico, 87102, United States
Albuquerque New Mexico, 87106, United States
Medford Oregon, 97504, United States
Buenos Aires , C1280, Argentina
Ciudad Autonoma Buenos Aires , C1426, Argentina
Birtinya Queensland, 4575, Australia
Clayton Victoria, 3168, Australia
Guangzhou , 51008, China
Jinan , 25011, China
Ningbo , , China
Shanghai , 20043, China
Tianjin , 30006, China
Busan , 602-7, Korea, Republic of
Cheongju si , 28644, Korea, Republic of
Daegu , 41404, Korea, Republic of
Gyeonggi-do , 16247, Korea, Republic of
Gyeongsangnam-do , 50612, Korea, Republic of
Jeollanam-do , 58128, Korea, Republic of
Seongnam-si , 463-7, Korea, Republic of
Seoul , 03722, Korea, Republic of
Seoul , 05505, Korea, Republic of
Seoul , 06351, Korea, Republic of
Ulsan , 44033, Korea, Republic of
Kaohsiung , 807, Taiwan
Taipei , 112, Taiwan
How clear is this clinincal trial information?